Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |